Analysts Offer Insights on Financial Companies: Morgan Stanley (MS) and Insurance Australia Group Limited (OtherIAUGF)
Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Morgan Stanley (MS – Research Report) and Insurance Australia Group Limited (IAUGF – Research Report).
Confident Investing Starts Here:
Morgan Stanley (MS)
In a report released yesterday, Ebrahim Poonawala from Bank of America Securities maintained a Buy rating on Morgan Stanley, with a price target of $143.00. The company's shares closed last Friday at $132.18.
According to TipRanks.com, Poonawala is a 5-star analyst with an average return of 11.8% and a 67.2% success rate. Poonawala covers the Financial sector, focusing on stocks such as Bank of New York Mellon Corporation, Canadian Bank of Commerce, and National Bank of Canada.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Morgan Stanley with a $133.25 average price target, implying a 0.7% upside from current levels. In a report issued on May 7, DBS also maintained a Buy rating on the stock with a $150.00 price target.
Insurance Australia Group Limited received a Hold rating and a A$9.30 price target from UBS analyst Kieren Chidgey today. The company's shares closed last Friday at $5.42, close to its 52-week high of $5.60.
According to TipRanks.com, Chidgey is a 2-star analyst with an average return of -1.2% and a 50.0% success rate. Chidgey covers the Financial sector, focusing on stocks such as QBE Insurance Group Limited, Computershare Limited, and Medibank Private.
Insurance Australia Group Limited has an analyst consensus of Moderate Buy, with a price target consensus of $5.58, a 2.9% upside from current levels. In a report issued on May 6, Morgan Stanley also maintained a Hold rating on the stock with a A$7.85 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
JPMorgan CEO Jamie Dimon warns economic conditions may deteriorate soon
JPMorgan Chase CEO Jamie Dimon issued a new warning about the U.S. economy, saying that conditions could deteriorate soon and undermine a potential soft landing. "I think there's a chance real numbers will deteriorate soon," Dimon said Tuesday at a Morgan Stanley conference. Dimon pushed back on suggestions that economic surveys showing diminished business and consumer confidence are an indicator of what's to come. He explained that "neither consumers nor businesses ever pick the inflection points," and added that the economy's "soft landing" will probably look weaker as conditions deteriorate. "Employment will come down a little bit. Inflation will go up a little bit. Hopefully, it's just a little bit," Dimon said, adding that reduced immigration could weaken the economy through its impact on the labor market. Jamie Dimon Says He's Not Afraid Of China, But Worries About America's Own Challenges Dimon also raised concerns regarding private credit markets if a recession materializes, saying that banks face different risks in that sector than investors and the current conditions in the sector have made private credit less attractive. Read On The Fox Business App "Do I think that now is a good time to buy credit if I was a fund manager? No," Dimon said. "I wouldn't be buying credit today at these prices and these spreads." Dimon has issued repeated warnings about the U.S. economy in recent months. Jamie Dimon Says A Recession Is Still A Possibility: 'I Wouldn't Take It Off The Table At This Point' In early April, he said in an appearance on FOX Business' "Mornings with Maria" that his personal view was that a recession is a "likely outcome" for the economy. Last month, Dimon said in a Bloomberg Television interview that a recession remained a possibility after the White House delayed and pared back some of its tariff plans to accommodate negotiations. "Hopefully we'll avoid it, but I wouldn't take it off the table at this point," Dimon said. "If there is a recession, I don't know how big it would be or how long it would last." Jpmorgan Lowers Recession Probability After Trump's Tariff Truce With China Dimon said that the uncertainty created by President Donald Trump's tariffs has caused some of the firm's clients to hold off on investments amid the shifts in policy, which have featured delays in the implementation of tariffs as well as changes in tariff levels as the administration negotiates with U.S. trading partners. "I think it's the right thing to do — is to back off of some of that stuff," Dimon said of the tariff pause for negotiations, adding that the two sides should "have an engaging conversation." Economists at JPMorgan lowered the probability of a recession this year from 60% to below 50% following the Trump administration's move to pare back some of the tariffs on China, which were set to be as high as 145% during a temporary 90-day article source: JPMorgan CEO Jamie Dimon warns economic conditions may deteriorate soon Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
Morgan Stanley sees strong retail momentum in life insurance; SBI Life leads May growth
By Markets Desk Published on June 12, 2025, 07:40 IST Morgan Stanley has observed a strong uptick in individual sum assured (SA) growth across the life insurance sector in May 2025, outpacing growth in annualised premium equivalent (APE), especially among large private insurers. SBI Life Insurance posted a stellar 68% year-on-year growth in individual new sum assured, driven by robust demand for retail protection products launched at the end of the second quarter of FY25. ICICI Prudential Life and HDFC Life Insurance also delivered healthy double-digit growth in individual SA, at 19% YoY and 14% YoY, respectively, reflecting improving sentiment in protection-linked products and a broader revival in life insurance demand. This strong monthly data comes amid a recovering macro environment and higher consumer awareness post-pandemic, especially for pure protection and long-term guaranteed products. Morgan Stanley believes that product innovation, distribution expansion, and regulatory support will continue to drive structural growth in the Indian life insurance sector. Disclaimer: The views and target prices mentioned are as stated by Morgan Stanley and do not represent the opinions or recommendations of this publication. Investors are advised to consult their financial advisors before making any investment decisions. Markets Desk at
Yahoo
5 hours ago
- Yahoo
Axsome's AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Biotech Stocks with Huge Upside Potential. The FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine has issued a Refusal to File letter for Axsome Therapeutics, Inc. (NASDAQ:AXSM) AXS-14 new drug application. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. The submission was deemed incomplete by the agency due to the use of an 8-week primary endpoint in one of the two supporting trials and a flexible-dose schedule. Vikram Purohit, an analyst at Morgan Stanley, stated that Axsome Therapeutics, Inc. (NASDAQ:AXSM) intends to start a fresh 12-week primary endpoint trial with a fixed dose in Q4. The stock is still rated as overweight by Morgan Stanley, which has set a price target of $190. AXS-14's regulatory setback is viewed as a temporary setback. The regulatory development of AXS-05 for Alzheimer's disease agitation and the commercial success of Auvelity in major depressive disorder are seen by Morgan Stanley as Axsome Therapeutics, Inc. (NASDAQ:AXSM)'s primary 2025 value drivers. The company is nevertheless optimistic about Axsome Therapeutics, Inc. (NASDAQ:AXSM)'s overall pipeline momentum and prospects for near-term revenue growth despite the AXS-14 filing struggle. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical business in the clinical stage. It is involved in the development of new treatments for conditions of the central nervous system or CNS, for which there are few available options. The business is among the stocks with the biggest upside. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
